Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:26:45 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:ACAD from 2023-04-27 to 2024-04-26 - 45 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-24 16:05U:ACADNews ReleaseAcadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
2024-04-22 09:04U:ACADNews ReleaseAcadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
2024-04-19 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-17 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Presents New DAYBUE(TM) (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
2024-04-02 16:05U:ACADNews ReleaseAcadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
2024-04-01 16:05U:ACADNews ReleaseAcadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
2024-03-15 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-13 16:05U:ACADNews ReleaseAcadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
2024-03-11 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
2024-02-29 09:05U:ACADNews ReleaseAcadia Pharmaceuticals to Participate in TD Cowen's 44th Annual Health Care Conference on March 6, 2024
2024-02-27 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
2024-02-21 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-13 16:05U:ACADNews ReleaseAcadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
2024-01-30 20:48U:ACADNews ReleaseAcadia Announces Additions to Executive Team
2024-01-19 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-18 16:05U:ACADNews ReleaseAcadia Announces the Passing of Former President Srdjan (Serge) Stankovic
2023-12-21 16:05U:ACADNews ReleaseAcadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
2023-12-18 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-13 21:24U:ACADNews ReleaseDelaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID ‚ ® (pimavanserin)
2023-12-13 13:41U:ACADNews ReleaseDelaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID ‚ ® (pimavanserin) Patent Litigation
2023-11-30 09:05U:ACADNews ReleaseAcadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome
2023-11-27 09:05U:ACADNews ReleaseAcadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer ¢ € ™s Disease Psychosis
2023-11-21 17:00U:ACADNews ReleaseAcadia Pharmaceuticals Announces Change in Research and Development Leadership
2023-11-14 16:12U:ACADNews ReleaseAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-02 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
2023-10-31 16:05U:ACADNews ReleaseAcadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference
2023-10-23 09:05U:ACADNews ReleaseAcadia Pharmaceuticals Announces the Rett Sibling Scholarship Program
2023-10-19 16:05U:ACADNews ReleaseAcadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023
2023-10-18 17:00U:ACADNews ReleaseAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-22 18:23U:ACADNews ReleaseAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-19 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications
2023-08-30 16:05U:ACADNews ReleaseAcadia Pharmaceuticals to Participate at Upcoming Investor Conferences
2023-08-14 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-02 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview
2023-08-01 19:30U:ACADNews ReleaseAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-07-24 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer
2023-07-19 16:04U:ACADNews ReleaseAcadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023
2023-07-13 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren ¢ € ™s NNZ-2591 in Rett Syndrome and Fragile X Syndrome
2023-06-26 17:00U:ACADNews ReleaseAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-13 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome
2023-06-08 11:10U:ACADNews ReleaseNature Medicine Publishes Results from Pivotal Phase 3 LAVENDER ¢ „ ¢ Study Evaluating DAYBUE ¢ „ ¢ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome
2023-06-01 09:04U:ACADNews ReleaseAcadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
2023-05-08 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
2023-05-05 16:04U:ACADNews ReleaseAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-02 09:04U:ACADNews ReleaseAcadia Pharmaceuticals to Present at Upcoming Investor Conferences